DENVER, Feb. 16 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that Lewis Rubin, M.D. will present
detailed results of AMB-220, the phase II study of ambrisentan in pulmonary
arterial hypertension ("PAH"), at the ATS 2004 International Conference.
Myogen previously disclosed summary results of the study in 2003. Dr. Rubin's
abstract has been selected for an oral presentation at a mini-symposium,
Emerging Therapies for PAH, Sunday, May 23, 2004, between 1:30 p.m. and
4:15 p.m. (Eastern). Dr. Rubin is Director of the Pulmonary Vascular Center
at the University of California, San Diego School of Medicine and a principal
investigator for AMB-220.
ATS 2004, the 100th International Conference of the American Thoracic
Society will be held May 21 - 26, 2004 at the Orange County Convention Center
in Orlando, Florida. Additional conference information is available at
http://www.thoracic.org/ic/ic2004 .
Myogen completed AMB-220 in September 2003. The study was a randomized,
double-blind, multi-center, dose-ranging phase II study evaluating the effect
of ambrisentan on exercise capacity of patients with moderate to severe PAH.
Exercise capacity was the primary efficacy endpoint and was measured as the
change from baseline in the six-minute walk test distance after 12 weeks of
treatment.
In January 2004, Myogen announced that it began patient enrollment in
ARIES I & II, the pivotal phase III clinical trials of ambrisentan for the
treatment of PAH.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of chronic heart failure, ambrisentan for the treatment of
pulmonary arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.thoracic.org/ic/ic2004
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
